Evidence map›Paper›PMID 31692373›Full record

ArticleDiabetes technology & therapeutics2020

Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes.

Ronnie Aronson, Edward Mahoney, Drilon Saliu, David Sze, Didier Morel, Leya Bergquist, Laurence Hirsch

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes technology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Ronnie AronsonLMC Diabetes and Endocrinology, Toronto, Canada.
Edward MahoneyMedical Affairs, Becton, Dickinson and Company, Franklin Lakes, New Jersey.
Drilon SaliuMedical Affairs, Becton, Dickinson and Company, Franklin Lakes, New Jersey.
David SzeMedical Affairs, Becton, Dickinson and Company, Franklin Lakes, New Jersey.
Didier MorelGlobal Clinical Development, Becton, Dickinson and Company, Le Pont de Claix, France.
Leya BergquistHuman Factors Engineering, R&D, Becton, Dickinson and Company, Franklin Lakes, New Jersey.
Laurence HirschMedical Affairs, Becton, Dickinson and Company, Franklin Lakes, New Jersey.
Becton Dickinson (United States) · USBecton Dickinson (France) · FRLMC Diabetes & Endocrinology (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsMaleMiddle AgedYoung AdultHypoglycemic AgentsInsulinGlycemic controlInsulin delivery deviceProspective studyType 2 diabetes

Identifiers

PMID31692373
PMCPMC7196361
OpenAlexW2989269490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.